Magnetic Jewelry Therapy

Bio Magnetic Therapy News

Mortal Kombat - Walkthrough & Moves ListThursday, July 7, 2011 @ 1:28AM* * ** *** *** ** * * * ** * * *** ** *** ** ** * * * * * * * * * * * * ** ** * * * * * * ** * * * *** * **** * *** * * * ** * *** **** * * * * * * * * * * * * * * * * * * * * * * * * ** ...

NYU Cancer Institute scientists present new research findings at ASCO 2011Wednesday, June 8, 2011 @ 6:50AMExperts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

New Biomarkers Allow For Better Diagnosis, Prognosis And Response-to-Treatment Evaluation In Multiple Sclerosis And ...Tuesday, May 31, 2011 @ 8:31AMBiomarkers - surrogates which can be objectively measured and used as indicators for certain biological states, salutogenetic or pathogenetic processes or responses to pharmacological treatments - are of increasing importance in many areas of modern medicine, but especially so in neuroscience. Neurological diseases are most complex in nature, sometimes difficult to detect, and when relying only ...

EURETINA honors Retina Implant founder with Innovation Awards in the field of artificial visionTuesday, May 31, 2011 @ 6:28AMRetina Implant AG today announced that the Company's founder Professor Eberhart Zrenner M.D. was awarded the second prize by The European Society for Retina Specialists.

Flex Fuels Energy, Inc., COAG Proof of Concept SuccessThursday, April 14, 2011 @ 7:30AMLONDON--(Marketwire - 04/14/11) - Flex Fuels Energy, Inc. ("Flex" or the "Company") (OTC.BB: FXFL - News ) announces a development milestone at its 63% owned subsidiary, BioAMD Holdings Limited ("Bio-AMD"). Bio-AMD is targeting its medical diagnostic device technologies at the fast growing Point of Care market. COAG blood coagulation monitor -- Proof of Concept Success Bio-AMD is pleased to ...

Gilenya can reduce risk of disability progression in patients with RRMSMonday, April 11, 2011 @ 1:40AMA new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

Bio-resonance therapyWednesday, March 16, 2011 @ 11:46PMLIFE is an energy phenomenon, and everything that happens in our body involves an energy exchange or movement.

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIVThursday, March 3, 2011 @ 2:04AMVertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

Handheld nanoLAB detects disease proteins in minutesWednesday, February 23, 2011 @ 3:26PMIn 2009, Stanford University faculty member Shan Wang and doctoral students Richard Gaster and Drew Hall demonstrated that they could use the same ultrasensitive magnetic sensors that form the basis of today's compact, high-capacity disk drives in combination with mass-produced magnetic nanotags to detect small amounts of cancer-associated proteins (click here for earlier story).